Scientific Plenary IV: Coming Attractions: Clinical Trials

Scientific Plenary


  • Katherine Fuh, MD, PhD Washington University in St. Louis, St. Louis, MO
  • Mark Shahin, MD, Abington Hospital-Jefferson Health, Hanjani Institute For Gynecologic Oncology, Abington, PA


  • Mary Jackson-Scroggins, In My Sister’s Care, Washington, DC

Location: Kamehameha 3

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase II summit ‘BASKET’ trial

A. D’Souza1, L.D. Roman2, C. Saura3, I. Braña3, G.I. Shapiro4, R. Passalacqua5, S. Piha-Paul6, R.E. Cutler Jr.7, S. Shahin7, L.D. Eli7, F. Xu7, M. Dujka7, A.S. Lalani7,
R. Bryce8, F. Meric-Bernstam6, D.B. Solit9 and D.M. Hyman9
1USC Norris Cancer Hospital, Los Angeles, CA, USA, 2USC Norris Comprehensive Cancer Hospital, Los Angeles, CA, USA, 3Vall d’Hebron University Hospital, Vall d’Hebrón Institute of Oncology, VHIO, Barcelona, Spain, 4Dana-Farber Cancer Institute, Boston, MA, USA, 5Istituti Ospitalieri di Cremona, Cremona, Italy, 6The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 7Puma Biotechnology Inc., South San Francisco, CA, USA, 8Puma Biotechnology Inc., Los Angeles, CA, USA, 9Memorial Sloan Kettering Cancer Center, New York, NY, USA

Tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated safety and efficacy results from the phase II INNOVA TV 201 study

D.S. Hong1, H.T. Arkenau2, J. de Bono3, U.N. Lassen4, Y. Drew5, B.M. Slomovitz6, S. Ghatta7, K. Windfeld8, R.A. Rangwala7 and N. Concin9 
1The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2Sarah Cannon Research Institute, London, United Kingdom, 3Cancer Research/Royal Marsden, London, United Kingdom, 4Rigshospitalet, Copenhagen, Denmark, 5Newcastle University, Northern Institute for Cancer Research, Newcastle-upon-Tyne, United Kingdom, 6University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA, 7Genmab US, Inc., Princeton, NJ, USA, 8Genmab, Copenhagen, Denmark, 9BGOG and University of Leuven, Leuven Cancer Institute, Leuven, Belgium

A randomized, open-label study comparing trabectedin and pegylated liposomal doxorubicin with pegylated liposomal doxorubicin alone for the treatment of
advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer (ET743-OVC-3006)

B.J. Monk1, T.J. Herzog2, S. Triantos3, G. Wang4, W.S.W. Shalaby5, T. McGowan5 and R.L. Coleman6
1Arizona Oncology (US Oncology Network); University of Arizona; Creighton University, Phoenix, AZ, USA, 2University of Cincinnati Cancer Institute, University
of Cincinnati, Cincinnati, OH, USA, 3Janssen Research & Development, Titusville, NJ, USA, 4Janssen Research & Development, Raritan, NJ, USA, 5Janssen Scientific
Affairs, LLC, Horsham, PA, USA, 6The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Molecular determinants of immune response in ovarian cancer racial disparity: Can selective immunotherapy optimize therapy and close the disparity gap?

L. Madeira da Silva1, D. Starenki2, J.M. Scalici1 and R.P. Rocconi1
1Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA, 2Genetics/Genomics, Huntsville, AL, USA

Minority participation in phase I gynecologic clinical trials: Three decades of inequity

E. Awad, M.L. Mattei, N.L. Jones, J.Y. Pierce, J.M. Scalici and R.P. Rocconi
Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA